Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2

P. Lissoni, A. Bastone, S. Barni, G. Tancini, M. A. Galli

Research output: Contribution to journalArticle

Abstract

It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.

Original languageEnglish
Pages (from-to)65-66
Number of pages2
JournalJournal of Biological Regulators and Homeostatic Agents
Volume8
Issue number2
Publication statusPublished - 1994

Fingerprint

immunotherapy
interleukin-2
Immunotherapy
hypertension
Interleukin-2
Blood Pressure
Hypertension
therapeutics
neoplasms
blood pressure
Neoplasms
Therapeutics
hypotension
dosage
Hypotension

Keywords

  • blood pressure
  • hypertension
  • interleukin-2

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Endocrinology
  • Physiology
  • Immunology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)

Cite this

Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2. / Lissoni, P.; Bastone, A.; Barni, S.; Tancini, G.; Galli, M. A.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 8, No. 2, 1994, p. 65-66.

Research output: Contribution to journalArticle

Lissoni, P. ; Bastone, A. ; Barni, S. ; Tancini, G. ; Galli, M. A. / Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2. In: Journal of Biological Regulators and Homeostatic Agents. 1994 ; Vol. 8, No. 2. pp. 65-66.
@article{99ca8055e97d411ba17aa8b5ac1b34f8,
title = "Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2",
abstract = "It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.",
keywords = "blood pressure, hypertension, interleukin-2",
author = "P. Lissoni and A. Bastone and S. Barni and G. Tancini and Galli, {M. A.}",
year = "1994",
language = "English",
volume = "8",
pages = "65--66",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "2",

}

TY - JOUR

T1 - Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2

AU - Lissoni, P.

AU - Bastone, A.

AU - Barni, S.

AU - Tancini, G.

AU - Galli, M. A.

PY - 1994

Y1 - 1994

N2 - It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.

AB - It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.

KW - blood pressure

KW - hypertension

KW - interleukin-2

UR - http://www.scopus.com/inward/record.url?scp=0028046303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028046303&partnerID=8YFLogxK

M3 - Article

C2 - 7863816

AN - SCOPUS:0028046303

VL - 8

SP - 65

EP - 66

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2

ER -